These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8297921)

  • 1. Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.
    Quirion R
    J Psychiatry Neurosci; 1993 Nov; 18(5):226-34. PubMed ID: 8297921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease.
    Quirion R; Aubert I; Lapchak PA; Schaum RP; Teolis S; Gauthier S; Araujo DM
    Trends Pharmacol Sci; 1989 Dec; Suppl():80-4. PubMed ID: 2694529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders.
    Whitehouse PJ; Kellar KJ
    J Neural Transm Suppl; 1987; 24():175-82. PubMed ID: 2960781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated nicotine exposure in rats: effects on memory function, cholinergic markers and nerve growth factor.
    Hernandez CM; Terry AV
    Neuroscience; 2005; 130(4):997-1012. PubMed ID: 15652996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness.
    Perry EK; Perry RH
    Brain Cogn; 1995 Aug; 28(3):240-58. PubMed ID: 8546852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease.
    Lai MK; Tsang SW; Garcia-Alloza M; Minger SL; Nicoll JA; Esiri MM; Wong PT; Chen CP; Ramírez MJ; Francis PT
    Neurobiol Dis; 2006 Jun; 22(3):555-61. PubMed ID: 16473016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: relationship with cholinergic and galaninergic perikarya.
    Mufson EJ; Jaffar S; Levey AI
    J Comp Neurol; 1998 Mar; 392(3):313-29. PubMed ID: 9511920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit.
    Gil-Bea FJ; García-Alloza M; Domínguez J; Marcos B; Ramírez MJ
    Neurosci Lett; 2005 Feb; 375(1):37-41. PubMed ID: 15664119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains.
    Nordberg A; Nilsson-Håkansson L; Adem A; Lai Z; Winblad B
    Prog Clin Biol Res; 1989; 317():1169-78. PubMed ID: 2557636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of acetylcholine release by presynaptic muscarinic autoreceptors.
    Re L
    Acta Physiol Pharmacol Ther Latinoam; 1999; 49(4):215-23. PubMed ID: 10797864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D5 receptor localization on cholinergic neurons of the rat forebrain and diencephalon: a potential neuroanatomical substrate involved in mediating dopaminergic influences on acetylcholine release.
    Berlanga ML; Simpson TK; Alcantara AA
    J Comp Neurol; 2005 Nov; 492(1):34-49. PubMed ID: 16175554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cholinergic treatment strategies in Alzheimer's disease].
    Kurz A; Rüster P; Romero B; Zimmer R
    Nervenarzt; 1986 Oct; 57(10):558-69. PubMed ID: 3785472
    [No Abstract]   [Full Text] [Related]  

  • 13. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
    Terry AV; Buccafusco JJ
    J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurochemical deficits in pathological brain aging: specificity and possible relevance for treatment strategies.
    Quirion R; Aubert I; Robitaille Y; Gauthier S; Araujo DM; Chabot JG
    Clin Neuropharmacol; 1990; 13 Suppl 3():S73-80. PubMed ID: 2093419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HT22 hippocampal neuronal cell line possesses functional cholinergic properties.
    Liu J; Li L; Suo WZ
    Life Sci; 2009 Feb; 84(9-10):267-71. PubMed ID: 19135458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M; Kálmán J
    Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A group of potassium-channel blockers-acetylcholine releasers: new potentials for Alzheimer disease? A review.
    Lavretsky EP; Jarvik LF
    J Clin Psychopharmacol; 1992 Apr; 12(2):110-8. PubMed ID: 1573033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbances in neurotransmission processes in aging and age-related diseases.
    Ossowska K
    Pol J Pharmacol; 1993; 45(2):109-31. PubMed ID: 8401765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitramine.
    Roffel AF; Davids JH; Elzinga CR; Wolf D; Zaagsma J; Kilbinger H
    Br J Pharmacol; 1997 Sep; 122(1):133-41. PubMed ID: 9298539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
    Goekoop R; Scheltens P; Barkhof F; Rombouts SA
    Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.